Clinical Trials in Netherlands

• A phase 2 study to investigate the effectiveness of combination immunotherapy followed by chemoradiation of the tumor in patients with bladd… Ended
  2024-512211-41-00 Phase I/II Urothelial carcinoma of the bladder and bladder cancer Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiation in sarcopenic head and neck cancer patients Ended
  2024-514919-10-00 Phase IV Locally advanced head and neck squamous cell carcinoma Universitair Medisch Centrum Utrecht
• Is there a survival benefit of administering thoracic radiotherapy concurrently with immunnotherapy and chemotherapy for patients with exten… Ended
  2023-505514-15-00 Phase III Small-cell lung cancer, extensive stage Norwegian University Of Science And Technolology
• A Study to Evaluate the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Profiles of CGT9486 in subjects with Advanced Systemic Mastocy… Ended
  2024-511407-42-00 Phase II Advanced Systemic Mastocytosis Cogent Biosciences Inc.
• A long term Investigation of the Safety and Efficacy of Odevixibat in Patients with Alagille syndrome Ended
  2023-509028-17-00 Phase III Alagille Syndrome Ipsen Pharma
• Prospective, randomized, neoadjuvant phase II study with combination immuno-oncology in primary clear cell renal cell cancer at risk for rec… Ended
  2024-515514-40-00 Phase II Resectable intermediate to high-risk clear cell RCC (accordi… Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myeloma Ended
  2023-503620-60-00 Phase I (Other) multiple myeloma Janssen - Cilag International
• A study to investigate the efficacy and safety of trastuzumab deruxtecan as the first treatment option for locally advanced/metastatic Non-S… Ended
  2023-503674-20-00 Phase III Unresectable, locally advanced, or metastatic Non-Small Cell… AstraZeneca AB
• This is a multicenter, randomized, Phase 3 study with vimseltinib or placebo in patients with Tenosynovial Giant Cell Tumor, consisting of 2… Ended
  2024-513624-42-00 Phase III Tenosynovial Giant Cell Tumor Deciphera Pharmaceuticals Inc.
• A research study to compare different doses of a new investigational medicinal product for treatment of certain patients with Duchenne muscu… Ended
  2024-511492-15-00 Phase III Duchenne Muscular Dystrophy Sarepta Therapeutics Inc.
• Phase I study of IAG933 in patients with advanced Mesothelioma and other solid tumors Ended
  2023-508369-34-00 Phase I Advanced mesothelioma or other solid tumors harboring certai… Novartis Pharma AG
• A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRA… Ended
  2023-506241-30-00 Phase III Advanced Colorectal Cancer with KRAS G12C Mutation Mirati Therapeutics Inc.
• A clinical study to assess the efficacy and safety of lanifibranor followed by an active treatment extension in adult patients with non-cirr… Ended
  2023-508248-23-00 Phase III Non-alcoholic steatohepatitis (NASH) Inventiva
• A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended
  2024-510735-21-00 Phase III Atherosclerotic cardiovascular disease (ASCVD) Novartis Pharma AG
• A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ez… Ended
  2024-514034-20-00 Phase I (Other) non-small cell lung cancer or Boehringer Ingelheim International GmbH
• A Clinical Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in … Ended
  2023-506518-33-00 Phase III Locally Advanced or Metastatic Non-Small Cell Lung Cancer Janssen - Cilag International
• Long-term safety and tolerability of iptacopan in patients with Paroxysmal Nocturnal Hemoglobinuria Ended
  2023-509843-28-00 Phase III Paroxysmal Nocturnal Hemoglobinuria (PNH) Novartis Pharma AG
• Anti-PD-1, Capecitabine, and Oxaliplatin for the first-line treatment of dMMR esophagogastric cancer (AuspiCiOus-dMMR): a proof-of-principle… Ended
  2023-509380-24-00 Phase II Metastatic upper gastrointestinal cancer, cancer of esophagu… Amsterdam UMC
• Treatment combination of Durvalumab, Tremelimumab, Enfortumab Vedotin in patients with muscle invasive bladder cancer ineligible to cisplati… Ended
  2023-507342-84-00 Phase III Bladder Cancer Astrazeneca AB
• Pembrolizumab/placebo plus paclitaxel with or without bevacizumab for platinum-resistant recurrent ovarian cancer. Ended
  2023-506177-35-00 Phase III/IV Ovarian, fallopian tube, or primary peritoneal carcinoma. Merck Sharp & Dohme LLC
• Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET Driven, Unresectable and Locally Advanced or Metastatic PRCC … Ended
  2022-503105-38-00 Phase III MET-driven, unresectable and locally advanced or metastatic … AstraZeneca AB
• A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gas… Ended
  2023-510319-20-00 Phase III Gastroesophageal Adenocarcinoma (GEA) Jazz Pharmaceuticals Ireland Limited
• A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexa… Ended
  2023-503441-55-00 Phase II Relapsed/Refractory Multiple Myeloma Janssen - Cilag International
• EMBER-3 A Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Participants with ER+, HER… Ended
  2023-506786-63-00 Phase III Breast Cancer Eli Lilly & Co.

Showing 1,081–1,104 of 1,891 trials